# Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma

> **NCT06068400** · NA · TERMINATED · sponsor: **Guangzhou Bio-gene Technology Co., Ltd** · enrollment: 1 (actual)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** BCMA/GPRC5D dual CAR-T

## Key facts

- **NCT ID:** NCT06068400
- **Lead sponsor:** Guangzhou Bio-gene Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-09-21
- **Primary completion:** 2024-02-02
- **Final completion:** 2024-02-02
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Due to corporate strategic adjustment.
- **Last updated:** 2026-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06068400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06068400, "Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06068400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*